{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:11:19Z","timestamp":1784196679725,"version":"3.55.0"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpm-2025-0612_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The sFlt-1\/PlGF ratio is a predictive biomarker for preeclampsia (PE)\u2013related outcomes. In women with signs of PE at\u00a0\u226434\u00a0weeks, it may guide the timing of antenatal corticosteroid (ACS) administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2025-0612_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 702 women presenting with signs of PE and\/or fetal growth restriction (FGR) between 22+0- and 33+6-weeks. High risk was defined as an sFlt-1\/PlGF ratio\u00a0\u226585. The predictive accuracy of the ratio for PE-related preterm birth at\u00a0\u226434+0\u00a0weeks was assessed using receiver operating characteristic (ROC) analysis. Differences in remaining pregnancy duration and gestational age at delivery between risk groups were analyzed using the log-rank test (p&lt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2025-0612_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 702 patients, 165 (23.5\u202f%) had a PE-related delivery\u00a0\u226434+0\u00a0weeks. A high sFlt-1\/PlGF ratio (\u226585) was observed in 128 (18.2\u202f%) women who received ACS and in 44 (6.3\u202f%) who didn\u2019t. The sFlt-1\/PlGF ratio predicted PE-related delivery at\u00a0\u226434+0\u00a0weeks\u00a0\u2013 and thus the need for ACS with an AUC of 0.95 (95\u202f% CI 0.93\u20130.97), yielding an optimal cut-off of 52.5 with sensitivity 87.9\u202f% (95\u202f% CI 82.0\u201392.0) and specificity 87.9\u202f% (95\u202f% CI 84.9\u201390.4). The median remaining pregnancy duration was 7.0\u00a0days (IQR 3.0\u201317.8), with delivery at 29+5\u00a0weeks (IQR 26+6\u201332+0) in women with ACS and a ratio\u00a0\u226585, vs. 60.0\u00a0days (IQR 42.0\u201380.0) and delivery at 38+1\u00a0weeks (IQR 37+0\u201339+3) in women with a ratio &lt;85 and no ACS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2025-0612_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In women with signs of PE and FGR &lt;34\u00a0weeks of gestation, the sFlt-1\/PlGF ratio is a strong predictor of PE-related preterm delivery and may support clinical decision-making regarding timely ACS administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpm-2025-0612","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:56:28Z","timestamp":1768388188000},"page":"533-542","source":"Crossref","is-referenced-by-count":1,"title":["Antenatal corticosteroid prophylaxis in women with increased sFlt-1\/PlGF ratio in the clinical routine\u00a0\u2013 A retrospective analysis"],"prefix":"10.1515","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9298-3442","authenticated-orcid":false,"given":"Lisa","family":"Lorenz-Meyer","sequence":"first","affiliation":[{"name":"Department of Obstetrics , Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Hackel\u00f6er","sequence":"additional","affiliation":[{"name":"Department of Obstetrics , Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Nonn","sequence":"additional","affiliation":[{"name":"Department of Obstetrics , Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Scheele","sequence":"additional","affiliation":[{"name":"Department of Obstetrics , Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Henrich","sequence":"additional","affiliation":[{"name":"Department of Obstetrics , Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Verlohren","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Fetal Medicine , University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"2026051215133574915_j_jpm-2025-0612_ref_001","doi-asserted-by":"crossref","unstructured":"Santana, DS, Silveira, C, Costa, ML, Souza, RT, Surita, FG, Souza, JP, et al.. Perinatal outcomes in twin pregnancies complicated by maternal morbidity: evidence from the WHO multicountry survey on maternal and newborn health. BMC Pregnancy Childbirth 2018;18:449. https:\/\/doi.org\/10.1186\/s12884-018-2082-9.","DOI":"10.1186\/s12884-018-2082-9"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_002","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force. Aspirin use to prevent preeclampsia and related morbidity and mortality: US preventive services task force recommendation statement. JAMA 2021;326:1186\u201391. https:\/\/doi.org\/10.1001\/jama.2021.14781.","DOI":"10.1001\/jama.2021.14781"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_003","doi-asserted-by":"crossref","unstructured":"Bujold, E, Roberge, S, Lacasse, Y, Bureau, M, Audibert, F, Marcoux, S, et al.. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402\u201314. https:\/\/doi.org\/10.1097\/aog.0b013e3181e9322a.","DOI":"10.1097\/AOG.0b013e3181e9322a"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_004","doi-asserted-by":"crossref","unstructured":"Rolnik, DL, Wright, D, Poon, LC, O\u2019Gorman, N, Syngelaki, A, Matallana, Cde P, et al.. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017;377:613\u201322. https:\/\/doi.org\/10.1056\/nejmoa1704559.","DOI":"10.1056\/NEJMoa1704559"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_005","doi-asserted-by":"crossref","unstructured":"Rana, S, Powe, CE, Salahuddin, S, Verlohren, S, Perschel, FH, Levine, RJ, et al.. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911\u20139. https:\/\/doi.org\/10.1161\/circulationaha.111.054361.","DOI":"10.1161\/CIRCULATIONAHA.111.054361"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_006","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins\u00a0\u2013 Obstetrics and the Society forMaternal-FetalMedicin. ACOG practice bulletin no. 204: fetal growth restriction. Obstet Gynecol 2019;133:e97\u2013109. https:\/\/doi.org\/10.1097\/AOG.0000000000003070.","DOI":"10.1097\/AOG.0000000000003070"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_007","unstructured":"Quality statement 5: corticosteroids for women between 24+0 and 33+6\u00a0weeks of pregnancy | preterm labour and birth | quality standards | NICE [Internet]. NICE; 2016. https:\/\/www.nice.org.uk\/guidance\/qs135\/chapter\/Quality-statement-5-Corticosteroids-for-women-between-240-and-336-weeks-of-pregnancy [Accessed 25 Jun 2025]."},{"key":"2026051215133574915_j_jpm-2025-0612_ref_008","doi-asserted-by":"crossref","unstructured":"B\u00fchrer, C, Felderhoff-M\u00fcser, U, Gembruch, U, Hecher, K, Kainer, F, Kehl, S, et al.. Fr\u00fchgeborene an der Grenze der Lebensf\u00e4higkeit (Entwicklungsstufe S2k, AWMF-Leitlinien-Register Nr. 024\/019, Juni 2020). Z Geburtshilfe Neonatol 2020;224:244\u201354. https:\/\/doi.org\/10.1055\/a-1230-0810.","DOI":"10.1055\/a-1230-0810"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_009","doi-asserted-by":"crossref","unstructured":"Liggins, GC, Howie, RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972;50:515\u201325. https:\/\/doi.org\/10.1542\/peds.50.4.515.","DOI":"10.1542\/peds.50.4.515"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_010","doi-asserted-by":"crossref","unstructured":"McGoldrick, E, Stewart, F, Parker, R, Dalziel, SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2020;12:CD004454. https:\/\/doi.org\/10.1002\/14651858.CD004454.pub4.","DOI":"10.1002\/14651858.CD004454.pub4"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_011","doi-asserted-by":"crossref","unstructured":"Bilardo, CM, Hecher, K, Visser, GHA, Papageorghiou, AT, Marlow, N, Thilaganathan, B, et al.. Severe fetal growth restriction at 26\u201332\u00a0weeks: key messages from the TRUFFLE study. Ultrasound Obstet Gynecol 2017;50:285\u201390. https:\/\/doi.org\/10.1002\/uog.18815.","DOI":"10.1002\/uog.18815"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_012","doi-asserted-by":"crossref","unstructured":"Mylrea-Foley, B, Thornton, JG, Mullins, E, Marlow, N, Hecher, K, Ammari, C, et al.. Perinatal and 2-year neurodevelopmental outcome in late preterm fetal compromise: the TRUFFLE 2 randomised trial protocol. BMJ Open 2022;12:e055543. https:\/\/doi.org\/10.1136\/bmjopen-2021-055543.","DOI":"10.1136\/bmjopen-2021-055543"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_013","unstructured":"Fetal growth restriction. Guideline of the DGGG, \u00d6EGGG and SGGG (S2k-Level, AWMF Registry No. 015\/080), 2024.http:\/\/www.awmf.org\/leitlinien\/detail\/ll\/015-080.html [Accessed 25 Jun 2025]."},{"key":"2026051215133574915_j_jpm-2025-0612_ref_014","doi-asserted-by":"crossref","unstructured":"Schmidt, LJ, Rieger, O, Neznansky, M, Hackel\u00f6er, M, Dr\u00f6ge, LA, Henrich, W, et al.. A machine-learning-based algorithm improves prediction of preeclampsia-associated adverse outcomes. Am J Obstet Gynecol 2022;227:77.e1\u201377.e30. https:\/\/doi.org\/10.1016\/j.ajog.2022.01.026.","DOI":"10.1016\/j.ajog.2022.01.026"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_015","doi-asserted-by":"crossref","unstructured":"Yang, X, Ballard, HK, Mahadevan, AD, Xu, K, Garmire, DG, Langen, ES, et al.. Predicting interval from diagnosis to delivery in preeclampsia using electronic health records. Nat Commun 2025;16:3496. https:\/\/doi.org\/10.1038\/s41467-025-58437-7.","DOI":"10.1038\/s41467-025-58437-7"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_016","doi-asserted-by":"crossref","unstructured":"Villala\u00edn, C, Herraiz, I, Dom\u00ednguez-Del Olmo, P, Angulo, P, Ayala, JL, Galindo, A. Prediction of delivery within 7\u00a0days after diagnosis of early onset preeclampsia using machine-learning models. Front Cardiovasc Med 2022;9:910701. https:\/\/doi.org\/10.3389\/fcvm.2022.910701.","DOI":"10.3389\/fcvm.2022.910701"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_017","unstructured":"Hypertensive disorders in pregnancy: diagnosis and therapy. Guideline of the German society of gynecology and obstetrics (S2k-Level, AWMF Registry No. 015\/018), 2024. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/015-018 [Accessed 25 Jun 2025]."},{"key":"2026051215133574915_j_jpm-2025-0612_ref_018","doi-asserted-by":"crossref","unstructured":"Thadhani, R, Lemoine, E, Rana, S, Costantine, MM, Calsavara, VF, Boggess, K, et al.. Circulating angiogenic factor levels in hypertensive disorders of pregnancy. NEJM Evid 2022;1:EVIDoa2200161. https:\/\/doi.org\/10.1056\/evidoa2200161.","DOI":"10.1056\/EVIDoa2200161"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_019","doi-asserted-by":"crossref","unstructured":"Stepan, H, Herraiz, I, Schlembach, D, Verlohren, S, Brennecke, S, Chantraine, F, et al.. Implementation of the sFlt-1\/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 2015;45:241\u20136. https:\/\/doi.org\/10.1002\/uog.14799.","DOI":"10.1002\/uog.14799"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_020","doi-asserted-by":"crossref","unstructured":"Siepen, C, Brennecke, S. Does a sFlt-1\/PlGF ratio result > 655 before 34\u00a0weeks\u2019 gestation necessitate preterm delivery within 2\u00a0days? A retrospective observational study. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet 2024;37:2371047. https:\/\/doi.org\/10.1080\/14767058.2024.2371047.","DOI":"10.1080\/14767058.2024.2371047"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_021","doi-asserted-by":"crossref","unstructured":"Stolz, M, Zeisler, H, Heinzl, F, Binder, J, Farr, A. An sFlt-1:PlGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia. Pregnancy Hypertens 2018;11:54\u201360. https:\/\/doi.org\/10.1016\/j.preghy.2018.01.001.","DOI":"10.1016\/j.preghy.2018.01.001"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_022","doi-asserted-by":"crossref","unstructured":"Dr\u00f6ge, LA, Perschel, FH, St\u00fctz, N, Gafron, A, Frank, L, Busjahn, A, et al.. Prediction of preeclampsia-related adverse outcomes with the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)\/PlGF (placental growth Factor)-Ratio in the clinical routine: a real-world study. Hypertens Dallas Tex 19792021;77:461\u201371. https:\/\/doi.org\/10.1161\/hypertensionaha.120.15146.","DOI":"10.1161\/HYPERTENSIONAHA.120.15146"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_023","doi-asserted-by":"crossref","unstructured":"Tranquilli, AL, Dekker, G, Magee, L, Roberts, J, Sibai, BM, Steyn, W, et al.. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens 2014;4:97\u2013104. https:\/\/doi.org\/10.1016\/j.preghy.2014.02.001.","DOI":"10.1016\/j.preghy.2014.02.001"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_024","doi-asserted-by":"crossref","unstructured":"Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin. Number 222. Obstet Gynecol 2020;135:e237\u201360. https:\/\/doi.org\/10.1097\/AOG.0000000000003891.","DOI":"10.1097\/AOG.0000000000003891"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_025","doi-asserted-by":"crossref","unstructured":"Saccone, G, Berghella, V. Antenatal corticosteroids for maturity of term or near term fetuses: systematic review and meta-analysis of randomized controlled trials. BMJ 2016;355:i5044. https:\/\/doi.org\/10.1136\/bmj.i5044.","DOI":"10.1136\/bmj.i5044"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_026","doi-asserted-by":"crossref","unstructured":"Griffin, M, Dennis, A, Roman, AS. Latency period to delivery among growth restricted fetuses with abnormal umbilical artery dopplers. Am J Obstet Gynecol 2022;226:S229\u201330. https:\/\/doi.org\/10.1016\/j.ajog.2021.11.389.","DOI":"10.1016\/j.ajog.2021.11.389"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_027","doi-asserted-by":"crossref","unstructured":"Daskalakis, G, Pergialiotis, V, Domell\u00f6f, M, Ehrhardt, H, Di Renzo, GC, Ko\u00e7, E, et al.. European guidelines on perinatal care: corticosteroids for women at risk of preterm birth. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2023;36:2160628. https:\/\/doi.org\/10.1080\/14767058.2022.2160628.","DOI":"10.1080\/14767058.2022.2160628"},{"key":"2026051215133574915_j_jpm-2025-0612_ref_028","doi-asserted-by":"crossref","unstructured":"Enengl, S, Oppelt, P, Stelzl, P, Scharnreitner, I, Altmann, R, Grienberger, J, et al.. Risk for imminent delivery in preeclampsia based on the sFlt-1\/PlGF ratio: do we need new cut-offs? Geburtshilfe Frauenheilkd 2025;85:190\u20139. https:\/\/doi.org\/10.1055\/a-2497-8104.","DOI":"10.1055\/a-2497-8104"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2025-0612\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2025-0612\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:22:26Z","timestamp":1778599346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2025-0612\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,22]]},"published-print":{"date-parts":[[2026,3,26]]}},"alternative-id":["10.1515\/jpm-2025-0612"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2025-0612","relation":{},"ISSN":["0300-5577","1619-3997"],"issn-type":[{"value":"0300-5577","type":"print"},{"value":"1619-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]}}}